Skip to main
OM

Outset Medical (OM) Stock Forecast & Price Target

Outset Medical (OM) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Outset Medical has demonstrated strong performance in console sales for Q3, surpassing expectations even with a major order deferred to the following quarter, indicating robust demand for its dialysis technology. The company is actively implementing cost reduction and efficiency initiatives aimed at improving service margins and reaching its longer-term gross margin target of 50%, with Q3 gross margins already showing steady improvement in the high-30s for FY25. Furthermore, Outset Medical is effectively managing its cash burn, tracking toward a target of less than $50 million in 2025, which is complemented by an expanding consumables ordering trend and a growing average order size in its Tablo pipeline.

Bears say

Outset Medical Inc. has lowered its full-year revenue guidance by approximately $7 million due to delays in enterprise deal timing and a reported sales miss in Q3, primarily driven by weak consumables revenue. Despite solid console revenue, the significant dip in consumable sales, particularly from acute care customers, suggests instability in what is typically a reliable revenue stream. Additionally, concerns regarding the new sales leadership and the impact of anticipated delayed enterprise deals into 2026 further contribute to a negative outlook for the company’s stock performance.

Outset Medical (OM) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outset Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outset Medical (OM) Forecast

Analysts have given Outset Medical (OM) a Buy based on their latest research and market trends.

According to 3 analysts, Outset Medical (OM) has a Buy consensus rating as of Feb 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outset Medical (OM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.